1. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study. Issue 4 (12th December 2022) Authors: Corren, Jonathan; Ambrose, Christopher S.; Griffiths, Janet M.; Hellqvist, Åsa; Lindsley, Andrew W.; Llanos, Jean‐Pierre; Colice, Gene; Menzies‐Gow, Andrew Journal: Clinical & experimental allergy Issue: Volume 53:Issue 4(2023) Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Issue 7 (July 2022) Authors: Wechsler, Michael E; Menzies-Gow, Andrew; Brightling, Christopher E; Kuna, Piotr; Korn, Stephanie; Welte, Tobias; Griffiths, Janet M; Sałapa, Kinga; Hellqvist, Åsa; Almqvist, Gun; Lal, Harbans; Kaur, Primal; Skärby, Tor; Colice, Gene; Cambursano, Victor H; Fernandez, Marcelo J; Scherbovsky, Ferna... Journal: Lancet Issue: Volume 10:Issue 7(2022) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Saxagliptin vs. glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. Issue 4 (25th January 2013) Authors: Göke, Burkhard; Gallwitz, Baptist; Eriksson, Johan G.; Hellqvist, Åsa; Gause‐Nilsson, Ingrid Journal: International journal of clinical practice Issue: Volume 67:Issue 4(2013) Page Start: 307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗